Literature DB >> 20008051

Home-based speech treatment for Parkinson's disease delivered remotely: a case report.

Gabriella A Constantinescu1, Deborah G Theodoros, Trevor G Russell, Elizabeth C Ward, Stephen J Wilson, Richard Wootton.   

Abstract

We investigated the validity and feasibility of online delivery of the Lee Silverman Voice Treatment (LSVT) for the treatment of the speech disorder of a patient with idiopathic Parkinson's disease. The treatment was delivered in 16 sessions to the participant's home, 90 km from the speech language pathologist. A PC-based videoconferencing system was used, operating at 128 kbit/s over the public telecommunications network. The patient achieved substantial improvements in vocal sound pressure levels during sustained vowel phonation (6.13 dB), reading (12.28 dB) and conversational monologue (11.32 dB). There were improvements in the duration of sustained vowel phonation (4 s). Improvements were also perceived in the degree of breathiness and roughness in the voice, and in overall speech intelligibility in conversation. The patient was very satisfied with the audio and video quality of the conferencing, and with the online treatment overall. He reported a preference for online sessions for the future management of his condition, rather than face-to-face treatment. Remote LSVT delivery was found to be feasible and effective.

Entities:  

Mesh:

Year:  2009        PMID: 20008051     DOI: 10.1258/jtt.2009.090306

Source DB:  PubMed          Journal:  J Telemed Telecare        ISSN: 1357-633X            Impact factor:   6.184


  9 in total

1.  Telemedicine in Neurological Disorders: Opportunities and Challenges.

Authors:  Martina Chirra; Luca Marsili; Linsdey Wattley; Leonard L Sokol; Elizabeth Keeling; Simona Maule; Gabriele Sobrero; Carlo Alberto Artusi; Alberto Romagnolo; Maurizio Zibetti; Leonardo Lopiano; Alberto J Espay; Ahmed Z Obeidat; Aristide Merola
Journal:  Telemed J E Health       Date:  2018-08-23       Impact factor: 3.536

2.  Telerehabilitation of Anomia in Primary Progressive Aphasia.

Authors:  Aaron M Meyer; Heidi R Getz; David M Brennan; Tang M Hu; Rhonda B Friedman
Journal:  Aphasiology       Date:  2015-09-04       Impact factor: 2.773

Review 3.  Telerehabilitation, virtual therapists, and acquired neurologic speech and language disorders.

Authors:  Leora R Cherney; Sarel van Vuuren
Journal:  Semin Speech Lang       Date:  2012-07-31       Impact factor: 1.761

4.  LSVT LOUD and LSVT BIG: Behavioral Treatment Programs for Speech and Body Movement in Parkinson Disease.

Authors:  Cynthia Fox; Georg Ebersbach; Lorraine Ramig; Shimon Sapir
Journal:  Parkinsons Dis       Date:  2012-03-15

5.  Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial.

Authors:  Meredith A Achey; Christopher A Beck; Denise B Beran; Cynthia M Boyd; Peter N Schmidt; Allison W Willis; Sara S Riggare; Richard B Simone; Kevin M Biglan; E Ray Dorsey
Journal:  Trials       Date:  2014-11-27       Impact factor: 2.279

6.  Simulated in-home teletreatment for anomia.

Authors:  Lambert Dechêne; Michel Tousignant; Patrick Boissy; Joël Macoir; Serge Héroux; Mathieu Hamel; Simon Brière; Catherine Pagé
Journal:  Int J Telerehabil       Date:  2011-12-20

7.  A Randomized Crossover Pilot Study of Telemedicine Delivered via iPads in Parkinson's Disease.

Authors:  Satoko Sekimoto; Genko Oyama; Taku Hatano; Fuyuko Sasaki; Ryota Nakamura; Takayuki Jo; Yasushi Shimo; Nobutaka Hattori
Journal:  Parkinsons Dis       Date:  2019-01-06

8.  Feasibility of a Telerehabilitation Adaptation of the Be Clear Speech Treatment Program for Non-Progressive Dysarthria.

Authors:  Brooke-Mai Whelan; Deborah Theodoros; Louise Cahill; Atiyeh Vaezipour; Adam P Vogel; Emma Finch; Anna Farrell; Elizabeth Cardell
Journal:  Brain Sci       Date:  2022-01-31

Review 9.  A scoping review of Australian allied health research in ehealth.

Authors:  Teresa Iacono; Kellie Stagg; Natalie Pearce; Alana Hulme Chambers
Journal:  BMC Health Serv Res       Date:  2016-10-04       Impact factor: 2.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.